


AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claim 1-61. (Canceled)

62. (Previously Presented) A compound of the formula:



wherein:

J is a linking functional group and is independently:

-C(=O)- or -O-C(=O)- or -C(=O)-O-;

Cy is a cyclyl group and is independently:

C₃₋₂₀carbocyclyl, C₃₋₂₀heterocyclyl, or C₅₋₂₀aryl;

and is optionally substituted;

Q¹ is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted;

If J is $-\text{O}-\text{C}(=\text{O})-$ or $\text{C}(=\text{O})-\text{O}-$, then:

Q^2 is an acid leader group, and is independently:

C_{1-8} alkylene;

and is optionally substituted;

or:

Q^2 is an acid leader group, and is independently:

C_{5-20} arylene;

C_{5-20} arylene- C_{1-7} alkylene;

C_{1-7} alkylene- C_{5-20} arylene; or,

C_{1-7} alkylene- C_{5-20} arylene- C_{1-7} alkylene;

and is optionally substituted;

if J is $-\text{C}(=\text{O})-$, then:

Q^2 is an acid leader group, and is independently:

C_{5-20} arylene;

C_{5-20} arylene- C_{1-7} alkylene;

C_{1-7} alkylene- C_{5-20} arylene; or,

C_{1-7} alkylene- C_{5-20} arylene- C_{1-7} alkylene;

and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers,
chemically protected forms, and prodrugs thereof.

63. (Previously Presented) A compound according to claim 62, wherein J is -O-
C(=O)- or -C(=O)-O-.

64. (Previously Presented) A compound according to claim 62, wherein J is -O-
C(=O)-.

65. (Previously Presented) A compound according to claim 62, wherein J is -
C(=O)-O-.

66. (Previously Presented) A compound according to claim 62, wherein J is -
C(=O)-.

67. (Previously Presented) A compound according to claim 62, wherein Q¹ is
independently a group of the formula:



wherein:

the ring independently has from 4 to 7 ring atoms;

Z is independently -CH₂-, -N(R^N)- or -O-;

R^N , if present, is independently -H, C_{1-7} alkyl, C_{5-20} aryl- C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and


Q^1 is optionally further substituted.

68. (Previously Presented) A compound according to claim 67, wherein Q^1 is independently a group of the formula:




wherein y is independently 1, 2, 3, or 4.


69. (Previously Presented) A compound according to claim 68, wherein Q^1 is independently selected from:




70. (Previously Presented) A compound according to claim 69, wherein Q¹ is independently:



71. (Previously Presented) A compound according to claim 69, wherein Q¹ is independently:



72. (Previously Presented) A compound according to claim 69, wherein Q¹ is independently:



73. (Previously Presented) A compound according to claim 67, wherein R^N, if present, is independently selected from: -H, -Me, -Et, -Ph, and -CH₂-Ph.

74. (Previously Presented) A compound according to claim 67, wherein R^N, if present, is independently -H.

75. (Previously Presented) A compound according to claim 62, wherein substituents on Q¹, if present, are independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, -NH₂, -NMe₂,
-NEt₂, morpholino, -CONH₂, -CONMe₂, -NHCOMe, and =O;

and wherein, if a substituent is on an arylene group, it may additionally be selected from: -Me, -Et, -iPr, -tBu, -CF₃.

76. (Previously Presented) A compound according to claim 62, wherein Cy is independently C₃₋₂₀carbocyclyl; and is optionally substituted.

77. (Previously Presented) A compound according to claim 62, wherein Cy is independently C₃₋₂₀heterocyclyl; and is optionally substituted.

78. (Previously Presented) A compound according to claim 62, wherein Cy is independently C₅₋₂₀aryl; and is optionally substituted.


79. (Previously Presented) A compound according to claim 62, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

80. (Previously Presented) A compound according to claim 62, wherein Cy is independently C₅₋₂₀aryl derived from one of the following:

benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole, benzothiofuran, fluorene, acridine, and carbazole; and is optionally substituted.

81. (Previously Presented) A compound according to claim 62, wherein Cy is independently C₅₋₂₀aryl derived from benzene and is optionally substituted.

82. (Previously Presented) A compound according to claim 62, wherein Cy is independently an optionally substituted phenyl group of the formula:



wherein n is independently an integer from 0 to 5, and

each R^A is independently a substituent.

83. (Previously Presented) A compound according to claim 82, wherein n is 0.

84. (Previously Presented) A compound according to claim 82, wherein n is 1, and the R^A group is in the 4'-position.

85. (Previously Presented) A compound according to claim 82, wherein n is 2, and one R^A group is in the 4'-position, and the other R^A group is in the 2'-position.

86. (Previously Presented) A compound according to claim 82, wherein n is 2, and one R^A group is in the 4'-position, and the other R^A group is in the 3'-position.

87. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) ester;

(2) amido;

(3) acyl;

- (4) halo;
- (5) hydroxy;
- (6) ether;
- (7) C₁₋₇alkyl; substituted C₁₋₇alkyl;
- (8) C₅₋₂₀aryl; substituted C₅₋₂₀aryl;
- (9) sulfonyl;
- (10) sulfonamido.

88. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

- (1) -C(=O)OR¹, wherein R¹ is independently C₁₋₇alkyl as defined in (7);
- (2) -C(=O)NR²R³, wherein each of R² and R³ is independently -H or C₁₋₇alkyl as defined in (7);
- (3) -C(=O)R⁴, wherein R⁴ is independently C₁₋₇alkyl as defined in (7) or C₅₋₂₀aryl as defined in (8);
- (4) -F, -Cl, -Br, -I;
- (5) -OH;

(6) $-OR^5$, wherein R^5 is independently C_{1-7} alkyl as defined in (7) or C_{5-20} aryl as defined in (8);

(7) C_{1-7} alkyl; substituted C_{1-7} alkyl;

halo- C_{1-7} alkyl;

amino- C_{1-7} alkyl;

carboxy- C_{1-7} alkyl;

hydroxy- C_{1-7} alkyl;

C_{1-7} alkoxy- C_{1-7} alkyl;

C_{5-20} aryl- C_{1-7} alkyl;

(8) C_{5-20} aryl; substituted C_{5-20} aryl;

(9) $-SO_2R^7$, wherein R^7 is independently C_{1-7} alkyl as defined in (7) or C_{5-20} aryl as defined in (8);

(10) $-SO_2NR^8R^9$, wherein each of R^8 and R^9 is independently -H or C_{1-7} alkyl as defined in (7).

89. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) $-C(=O)OMe$, $-C(=O)OEt$, $-C(=O)OPr$, $-C(=O)OiPr$, $-C(=O)O(nBu)$,
 $-C(=O)O(sBu)$, $-C(=O)O(iBu)$, $-C(=O)O(tBu)$, $-C(=O)O(nPe)$;

-C(=O)OCH₂CH₂OH, -C(=O)OCH₂CH₂OMe, -C(=O)OCH₂CH₂OEt;

(2) -(C=O)NH₂, -(C=O)NMe₂, -(C=O)NEt₂, -(C=O)N(iPr)₂,

-(C=O)N(CH₂CH₂OH)₂;

(3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;

(4) -F, -Cl, -Br, -I;

(5) -OH;

(6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh;

-OCF₃, -OCH₂CF₃;

-OCH₂CH₂OH, -OCH₂CH₂OMe, -OCH₂CH₂OEt;

-OCH₂CH₂NH₂, -OCH₂CH₂NMe₂, -OCH₂CH₂N(iPr)₂;

-OPh, -OPh-Me, -OPh-OH, -OPh-OMe, O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-

I;

(7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe;

-CF₃, -CH₂CF₃;

-CH₂CH₂OH, -CH₂CH₂OMe, -CH₂CH₂OEt;

-CH₂CH₂NH₂, -CH₂CH₂NMe₂, -CH₂CH₂N(iPr)₂;

-CH₂-Ph;

(8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;

(9) -SO₂Me, -SO₂Et, -SO₂Ph;

(10) -SO₂NH₂, -SO₂NMe₂, -SO₂NEt₂.

90. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

-C(=O)OMe, -OMe, -C(=O)Me, -SO₂Me, -SO₂NMe₂, -C(=O)NH₂, -OCF₃,
and -CH₂CH₂OH.

91. (Previously Presented) A compound according to claim 62, wherein the acid leader group, Q², is independently:

C₅₋₂₀arylene;

and is optionally substituted.

92. (Previously Presented) A compound according to claim 62, wherein Q² is independently C₅₋₆arylene; and is optionally substituted.

93. (Previously Presented) A compound according to claim 62, wherein Q² is independently phenylene; and is optionally substituted.

94. (Previously Presented) A compound according to claim 93, wherein the phenylene linkage is meta or para.

95. (Previously Presented) A compound according to claim 93, wherein the phenylene linkage is meta.

96. (Previously Presented) A compound according to claim 93, wherein the phenylene linkage is para.

97. (Previously Presented) A compound according to claim 91, wherein Q^2 is independently unsubstituted.

98. (Previously Presented) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O- and the acid leader group, Q^2 , is independently:

C_{1-8} alkylene;

and is optionally substituted.

99. (Previously Presented) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O- and Q^2 is independently:

(a) a saturated C_{1-7} alkylene group; or:

(b) a partially unsaturated C_{2-7} alkylene group; or:

(c) an aliphatic C_{1-7} alkylene group; or:

(d) a linear C_{1-7} alkylene group; or:

(e) a branched C_{2-7} alkylene group; or:

(f) a saturated aliphatic C_{1-7} alkylene group; or:

(g) a saturated linear C₁₋₇alkylene group; or:

(h) a saturated branched C₂₋₇alkylene group; or:

(i) a partially unsaturated aliphatic C₂₋₇alkylene group; or:

(j) a partially unsaturated linear C₂₋₇alkylene group; or:

(k) a partially unsaturated branched C₂₋₇alkylene group;

and is optionally substituted.

100. (Previously Presented) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O- and Q² is independently selected from:

-(CH₂)₅-; -(CH₂)₆-; -(CH₂)₇-; and -(CH₂)₈-.

101. (Previously Presented) A compound according to claim 62, wherein Q² is independently:

C₅₋₂₀arylene-C₁₋₇alkylene;

C₁₋₇alkylene-C₅₋₂₀arylene; or,

C₁₋₇alkylene-C₅₋₂₀arylene-C₁₋₇alkylene;

and is optionally substituted.

102. (Previously Presented) A compound according to claim 62, wherein Q² is independently:

C₅₋₆arylene-C₁₋₇alkylene;

C₁₋₇alkylene-C₅₋₆arylene; or,

C₁₋₇alkylene-C₅₋₆arylene-C₁₋₇alkylene;

and is optionally substituted.

103. (Previously Presented) A compound according to any claim 62, wherein Q² is independently:

phenylene-C₁₋₇alkylene;

C₁₋₇alkylene-phenylene; or,

C₁₋₇alkylene-phenylene-C₁₋₇alkylene;

and is optionally substituted.

104. (Previously Presented) A compound according to claim 62, wherein Q² independently has a backbone of from 5 to 6 atoms.


105. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Q², if present, is independently selected from:

halo, hydroxy, ether, C₁₋₇alkoxy, C₅₋₂₀aryl, acyl, amino, amido, acylamido, nitro, and oxo; and wherein, if a substituent is on an arylene group, it may additionally be selected from: C₁₋₇alkyl and substituted C₁₋₇alkyl.

106. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Q², if present, is independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, -NH₂, -NMe₂, -NEt₂, morpholino, -CONH₂, -CONMe₂, -NHCOMe, -NO₂, and =O; and wherein, if a substituent is on an arylene group, it may additionally be selected from: -Me, -Et, -iPr, -tBu, -CF₃.


107. (Previously Presented) A compound of the formula:



wherein:

J is independently: -C(=O)-O-;

Q¹ is independently:







Q² is phenylene, and is optionally substituted;





Cy is phenyl, and is optionally substituted;





and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.





108. (Previously Presented) A compound selected from the following compounds, and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof:




1		PX118478
---	--	----------





2		PX118479
3		PX118480
4		PX119101
5		PX118925

6		PX118926
7		PX118959
8		PX118966
9		PX119058

10		PX119059
11		PX119061
12		PX119062
13		PX119064

14		PX119065
15		PX119084
16		PX119100
17		PX119063

18		PX119085
19		PX119086
20		PX119102

21		PX119103
22		
23		
24		

109. (Previously Presented) A composition comprising a compound according to claim 62 and a pharmaceutically acceptable carrier.

110. (Withdrawn - Currently Amended) A method of inhibiting HDAC in a cell comprising contacting said cell with an effective amount of a compound according to claim 62.

Claim 111. (Canceled)

112. (Withdrawal) A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound according to claim 62.

113. (Withdrawn) A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound according to claim 62.

114. (Withdrawn) A method for the treatment of psoriasis comprising administering to a subject suffering from psoriasis a therapeutically-effective amount of a compound according to claim 62.